Display options
Cite
Razavi P, Rand KA, Cozen W, et al. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J. 2013;3:e121doi: 10.1038/bcj.2013.19.
Razavi, P., Rand, K. A., Cozen, W., Chanan-Khan, A., Usmani, S., & Ailawadhi, S. (2013). Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood cancer journal, 3e121. https://doi.org/10.1038/bcj.2013.19
Razavi, P, et al. "Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics." Blood cancer journal vol. 3 (2013): e121. doi: https://doi.org/10.1038/bcj.2013.19
Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J. 2013 Jun 28;3:e121. doi: 10.1038/bcj.2013.19. PMID: 23811785; PMCID: PMC3698537.
Copy Download .nbib Format: NLM
Share it on

Blood Cancer J. 2013 Jun 28;3:e121. doi: 10.1038/bcj.2013.19.

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics.

Blood cancer journal

P Razavi, K A Rand, W Cozen, A Chanan-Khan, S Usmani, S Ailawadhi

Affiliations

  1. 1] Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA [2] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

PMID: 23811785 PMCID: PMC3698537 DOI: 10.1038/bcj.2013.19

Abstract

Recent studies have reported an increased risk of second primary malignancies (SPM) following multiple myeloma (MM) diagnosis associated with novel anti-myeloma treatments. We evaluated the risk of SPM among 36 491 MM cases reported to the Surveillance, Epidemiology, and End Results program (SEER) between 1973 and 2008. We calculated overall and site-specific standardized incidence ratio (SIR) and 95% confidence intervals (CI) for 2012 SPM cases diagnosed within the 35-year follow-up. There was no significant overall risk of SPM (SIR=0.98; 95% CI=0.94-1.02); however, there were multiple site-specific risk patterns. The risk of breast and prostate cancer was significantly decreased overall and across age, latency and the year of diagnosis strata. There was an ∼50% increased risk of colorectal cancer 5 years after MM diagnosis (Ptrend<0.001). The risk of hematological malignancies was significantly increased, notably for acute myeloid leukemia (AML; SIR=6.51; 95% CI=5.42-7.83). There was a significant decreasing trend for AML over time, particularly for patients 65. However, no significant change in risk was noted after the introduction of autologous stem cell transplant among younger patients (<65 years). On the basis of observed trends for overall SPM as well as AML, no association between the introduction of novel therapies and SPM following MM has emerged in this large population-based study.

References

  1. N Engl J Med. 1996 Jul 11;335(2):91-7 - PubMed
  2. N Engl J Med. 2003 Jun 26;348(26):2609-17 - PubMed
  3. Br J Cancer. 2001 Sep 28;85(7):997-1005 - PubMed
  4. Br J Haematol. 2007 Sep;138(5):563-79 - PubMed
  5. Blood. 2011 Oct 13;118(15):4086-92 - PubMed
  6. Leuk Lymphoma. 2011 Feb;52(2):247-59 - PubMed
  7. N Engl J Med. 2012 May 10;366(19):1770-81 - PubMed
  8. N Engl J Med. 1979 Oct 4;301(14):743-8 - PubMed
  9. Blood. 2012 Mar 29;119(13):3003-15 - PubMed
  10. N Engl J Med. 1999 Nov 18;341(21):1565-71 - PubMed
  11. N Engl J Med. 2012 May 10;366(19):1759-69 - PubMed
  12. Bone Marrow Transplant. 2007 Oct;40(8):759-64 - PubMed
  13. Oncology. 1977;34(1):20-4 - PubMed
  14. Br J Haematol. 1996 Nov;95(2):349-53 - PubMed
  15. JAMA. 2011 Nov 2;306(17):1891-901 - PubMed
  16. N Engl J Med. 2003 May 8;348(19):1875-83 - PubMed
  17. Br J Cancer. 1987 May;55(5):523-9 - PubMed
  18. Blood. 2012 Mar 22;119(12):2731-7 - PubMed
  19. Eur J Haematol. 2000 Aug;65(2):123-7 - PubMed
  20. Blood. 2008 Mar 1;111(5):2516-20 - PubMed
  21. N Engl J Med. 2012 May 10;366(19):1782-91 - PubMed
  22. J Hum Genet. 2008;53(6):499-507 - PubMed
  23. Int J Cancer. 2000 Feb 15;85(4):453-6 - PubMed
  24. Blood. 2008 Mar 15;111(6):2962-72 - PubMed
  25. Blood. 2005 Dec 15;106(13):4050-3 - PubMed
  26. Lancet. 1983 Oct 8;2(8354):822-4 - PubMed
  27. Prostate Cancer Prostatic Dis. 2012 Sep;15(3):244-9 - PubMed
  28. J Gastroenterol Hepatol. 2000 Nov;15(11):1272-6 - PubMed

Publication Types